A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Trial Profile

A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Bavituximab (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 08 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 12 Feb 2016 Status changed from planning to not yet recruiting as per ClinicalTrials.gov record.
    • 13 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top